B2493

Section 1

L.N. 119 of 2016

Pharmacy and Poisons (Amendment) (No. 4) Regulation 2016

(Made by the Pharmacy and Poisons Board under section 29(1B) of the Pharmacy and Poisons Ordinance (Cap. 138) subject to the approval of the Secretary for Food and Health)

1. Pharmacy and Poisons Regulations amended

The Pharmacy and Poisons Regulations (Cap. 138 sub. leg. A) are amended as set out in sections 2, 3 and 4.

- 2. Schedule 1 amended (substances to which certain restrictions with respect to the sale, supply, labelling and storage apply under regulations 3, 5, 6, 22 and 24)
 - (1) Schedule 1, Division A, after item "Alglucosidase alfa"—
 Add
 - "Alirocumab".
 - (2) Schedule 1, Division A, after item "Becaplermin; its salts"—

Add

"Bedaquiline; its salts".

- (3) Schedule 1, Division A, after item "Cobicistat; its salts"—

 Add
 - "Cobimetinib; its salts".
- (4) Schedule 1, Division A, after item "Ibrutinib; its salts"—

 Add
 - "Idarucizumab".

Section 3

(5) Schedule 1, Division A, after item "Lumefantrine; its salts"—

Add

"Lurasidone; its salts".

(6) Schedule 1, Division A, after item "Panitumumab"—

Add

"Panobinostat; its salts".

(7) Schedule 1, Division A, after item "Ruxolitinib; its salts"—

Add

"Sacubitril; its salts".

(8) Schedule 1, Division A, after item "Siltuximab"—

Add

"Simeprevir; its salts".

- 3. Schedule 3 amended (substances required by regulation 9 to be sold by retail only upon a prescription given by a registered medical practitioner, registered dentist or registered veterinary surgeon)
 - (1) Schedule 3, Division A, after item "Alglucosidase alfa"—

Add

"Alirocumab".

(2) Schedule 3, Division A, after item "Becaplermin; its salts"—

Add

"Bedaquiline; its salts".

(3) Schedule 3, Division A, after item "Cobicistat; its salts"—

Add

B2497

"Cobimetinib; its salts".

(4) Schedule 3, Division A, after item "Ibrutinib; its salts"—

Add

"Idarucizumab".

(5) Schedule 3, Division A, after item "Lumefantrine; its salts"—

Add

"Lurasidone; its salts".

(6) Schedule 3, Division A, after item "Panitumumab"—

Add

"Panobinostat; its salts".

(7) Schedule 3, Division A, after item "Ruxolitinib; its salts"—

Add

"Sacubitril; its salts".

(8) Schedule 3, Division A, after item "Siltuximab"—

Add

"Simeprevir; its salts".

4. Schedule 10 amended (Poisons List)

(1) Schedule 10, section 2, Table, Part 1, Division A, after item "Alglucosidase alfa"—

Add

"Alirocumab".

(2) Schedule 10, section 2, Table, Part 1, Division A, after item "Becaplermin; its salts"—

Add

"Bedaquiline; its salts".

(3) Schedule 10, section 2, Table, Part 1, Division A, after item "Cobicistat; its salts"—

Add

"Cobimetinib; its salts".

(4) Schedule 10, section 2, Table, Part 1, Division A, after item "Ibuprofen; its salts"—

Add

"Idarucizumab".

(5) Schedule 10, section 2, Table, Part 1, Division A, after item "Lumefantrine; its salts"—

Add

"Lurasidone; its salts".

(6) Schedule 10, section 2, Table, Part 1, Division A, after item "Panitumumab"—

Add

"Panobinostat; its salts".

(7) Schedule 10, section 2, Table, Part 1, Division A, after item "Ruxolitinib; its salts"—

Add

"Sacubitril; its salts".

(8) Schedule 10, section 2, Table, Part 1, Division A, after item "Siltuximab"—

Add

"Simeprevir; its salts".

L.N. 119 of 2016 B2501

Dr. Constance CHAN Chairman, Pharmacy and Poisons Board

3 October 2	2016	

L.N. 119 of 2016 B2503

Explanatory Note

This Regulation—

- (a) adds 8 items to Division A of Schedule 1, and Division A of Schedule 3, to the Pharmacy and Poisons Regulations (Cap. 138 sub. leg. A) (*principal Regulations*) so that the sale, supply, labelling and storage of substances in those items are subject to the restrictions imposed under the Pharmacy and Poisons Ordinance (Cap. 138) and the principal Regulations; and
- (b) adds 8 items to Division A of Part 1 of the Poisons List set out in Schedule 10 to the principal Regulations so that, among other applicable requirements, substances in those items can only be sold on registered premises of an authorized seller of poisons by a registered pharmacist or in the presence and under the supervision of a registered pharmacist.